Patient Selection

Patients with moderate cellulite and little to no laxity may be appropriate candidates for Qwo®

Adult woman’s buttock before QWO treatment

Are your patients appropriate for QWO?

Consider these factors when screening patients:1

  1. Cellulite Dimpling vs. Laxity: QWO is indicated for cellulite – not laxity
  2. Cellulite Location: Dimpling on the buttocks
  3. Cellulite Severity: Moderate to severe cellulite

Cellulite vs. Laxity

QWO is indicated for cellulite - not laxity.1 Patients with well-defined dimples and some laxity can still be good candidates for QWO, but the treatment may only improve cellulite dimples.1

Adult woman’s buttock with circles to show variations of acceptable laxity
What is cellulite?

Cellulite dimples are in part caused by collagenous fibrous septae that firmly anchor and allow fat to protrude.7,8

QWO Lyses Fibrous Septae

Since dimples represent the tethering of the fibrous septae, the appearance of cellulite may be improved if the septae are enzymatically subcized.2,7,8

Adult woman’s buttock with arrows pointing to variations of acceptable laxity
What is laxity?

Skin laxity, or looseness, is caused by a loss of collagen and/or elastin along with gravity working on the weight of subcutaneous structures, creating alterations to the skin’s surface.12

No Bands to Lyse

Lax skin indicates a loss of collagen and elastin, not a distinct tethering by collagen between skin layers.12

Looking for more information?

Additional information on cellulite vs laxity can be found in our Clinical Education Center.

Indication

Qwo® is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

Important Safety Information for QWO

Contraindications

QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

Warnings and Precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions including anaphylaxis have been reported with the use of collagenase clostridium histolyticum. If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

Injection Site Bruising

In clinical trials, 84% of subjects treated with QWO experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking ≤150 mg aspirin daily) were excluded from participating in Trials 1 and 2.

QWO should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet (except those taking ≤150 mg aspirin daily) or anticoagulant therapy.

Substitution of Collagenase Products

QWO must not be substituted with other injectable collagenase products.

QWO is not intended for the treatment of Peyronie’s Disease or Dupuytren’s Contracture.

Adverse Reactions

In clinical trials, the most commonly reported adverse reactions in patients treated with QWO with an incidence ≥ 10% were at the injection site: bruising, pain, nodule and pruritus.

View Full Prescribing Information for QWO.